Tirzepatide Beyond Weight Loss: Sleep Apnea, Diabetes & Heart
Released: Last reviewed:
Tirzepatide treats far more than weight. Here is every FDA-approved indication in 2026 — plus what is still under investigation.
By Dr. Parmis, Lead Medical Researcher · Medically reviewed by Adam Kennah, M.D. · Last reviewed July 9, 2026 · Sources cited at the end.
Direct answer
Tirzepatide is more than a weight-loss drug. It is FDA-approved for type 2 diabetes (Mounjaro, 2022), chronic weight management (Zepbound, 2023), and moderate-to-severe obstructive sleep apnea with obesity (Zepbound, 2024) — the first drug ever approved for OSA. Cardiovascular outcomes (SURPASS-CVOT) and liver disease (MASH) are under study but not yet approved indications for tirzepatide as of July 9, 2026.
Approved and emerging indications
| Indication | Brand | Status | Evidence |
|---|---|---|---|
| Type 2 diabetes | Mounjaro | Approved (May 2022) | SURPASS program (A1c down up to ~2.5%) |
| Chronic weight management | Zepbound | Approved (Nov 2023) | SURMOUNT-1 / -2 |
| Obstructive sleep apnea | Zepbound | Approved (Dec 2024) | SURMOUNT-OSA |
| Cardiovascular outcomes | — | Under study | SURPASS-CVOT (ongoing) |
| MASH (liver) | — | Investigational | Not FDA-approved for tirzepatide |
Sources: FDA/Lilly approval records; ClinicalTrials.gov.
Sleep apnea: a landmark approval
In SURMOUNT-OSA, tirzepatide sharply cut the apnea-hypopnea index. Among participants not using PAP therapy, it reduced breathing disruptions far more than placebo.
Diabetes and metabolic effects
As Mounjaro, tirzepatide lowers blood sugar substantially (A1c reductions up to roughly 2.5% in the SURPASS program) alongside weight loss, and it improves several cardiometabolic markers such as blood pressure and lipids. Whether that translates into fewer heart attacks and strokes is exactly what the SURPASS-CVOT outcomes trial is designed to answer.
What this means for patients
The right brand and indication depend on your diagnosis: Mounjaro for diabetes, Zepbound for weight or sleep apnea. Off-label use is possible but coverage is limited. Compounded tirzepatide is not FDA-approved for any indication. For the weight-loss data specifically, see weight loss by dose; for how tirzepatide works, see our mechanism guide.
Mounjaro vs Zepbound: same molecule, different brands
A common source of confusion: Mounjaro and Zepbound are the same drug (tirzepatide) sold under different names for different approved uses. Mounjaro carries the type 2 diabetes indication; Zepbound carries the weight-management and obstructive-sleep-apnea indications. The brand split matters for insurance, since coverage often keys to the indication and the specific product prescribed rather than the molecule itself.
Coverage and off-label realities
Insurance coverage varies widely and continues to evolve, especially for obesity and sleep apnea. A clinician can prescribe either brand off-label, but plans frequently decline to cover off-label use, which can make the out-of-pocket cost substantial. Emerging areas like cardiovascular protection and liver disease may broaden the approved-use picture over time, but until trials read out and the FDA acts, those remain investigational for tirzepatide. Match the diagnosis to the correct brand and confirm coverage before committing.
Frequently asked questions
What is tirzepatide approved for? Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes (2022) and as Zepbound for chronic weight management (2023) and for moderate-to-severe obstructive sleep apnea with obesity (2024).
Is tirzepatide approved for heart disease? Not as a standalone cardiovascular indication as of 2026. A cardiovascular outcomes trial, SURPASS-CVOT, is studying that question.
Does tirzepatide help sleep apnea? Yes — in SURMOUNT-OSA it substantially reduced breathing disruptions, leading to the first-ever FDA drug approval for obstructive sleep apnea in December 2024.
What about liver disease (MASH)? Tirzepatide has shown promise in MASH research, but it is not FDA-approved for MASH as of 2026. Semaglutide (Wegovy) added a MASH indication earlier in 2026.
July 9, 2026: Published; indications verified against FDA/Lilly approval records.
Reviewed by Adam Kennah, M.D.
Sources
- Eli Lilly — FDA approves Zepbound for obstructive sleep apnea — Dec 2024
- Drugs.com — Zepbound FDA approval history
- Narrative review — tirzepatide across SURPASS/SURMOUNT/SUMMIT (PMC)
Important: Compounded tirzepatide is not FDA-approved and is not the same medicine as Mounjaro or Zepbound, the only FDA-approved tirzepatide products (Eli Lilly and Company). This page is educational and is not medical or legal advice. Weight-loss medications require evaluation and, when appropriate, a prescription from a licensed clinician. Individual results and side effects vary. Confirm current FDA status, pricing, and clinical guidance directly before acting.